Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents
Treatment of Femoropopliteal In-Stent Restenosis With Paclitaxel-Eluting Stents
复制标题
DOI：
10.1016/j.jcin.2012.12.118
复制
发表时间：
2013-03-01
影响因子：
11.3
通讯作者：
Rastan, Aljoscha
中科院分区：
文献类型：
--
作者：
Zeller, Thomas;Dake, Michael D.;Rastan, Aljoscha
目的评价药物洗脱支架治疗股动脉支架内再狭窄(ISR)的疗效。虽然药物洗脱支架在治疗冠状动脉ISR中的作用已经明确，但还没有发表的研究探讨药物洗脱支架在治疗股骨干ISR中的作用。方法这项研究调查了108名患者，共119个ISR病变。结果患者平均年龄68.3±9.4岁，男性占61.1%。病变平均长度为133.0+/-91.7 mm，33.6%的病变长度为150 mm，31.1%的病变完全闭塞。98.2%的病变成功，每个病变放置2.1+/-1.2个支架。术后6个月和1年的初次通畅率分别为95.7%和78.8%。术后6个月、1年和2年的靶病变血管重建率分别为96.2%、81.0%和60.8%。40名患者经历了主要的不良事件，完全是靶点病变血管重建。治疗前，81.1%的患者卢瑟福评分为3；治疗2年后，60.9%的患者卢瑟福评分。
Objectives This study sought to evaluate the outcomes of drug-eluting stent treatment for femoropopliteal in-stent restenosis (ISR).Background ISR after femoropopliteal interventions is an increasing problem. Although the role of drug-eluting stents in the treatment of coronary ISR is well defined, no published studies have examined drug-eluting stents in the treatment of femoropopliteal ISR.Methods This study examines 108 patients with 119 ISR lesions who were enrolled in the ZILVER-PTX single-arm study, a prospective, multicenter clinical trial of 787 patients. All patients were treated with paclitaxel-eluting nitinol stents.Results Mean patient age was 68.3 +/- 9.4 years; 61.1% of patients were men. Mean lesion length was 133.0 +/- 91.7 mm; 33.6% of lesions were >150 mm long and 31.1% of lesions were totally occluded. Procedural success was achieved in 98.2% of lesions with 2.1 +/- 1.2 stents placed per lesion. Primary patency was 95.7% at 6 months and 78.8% at 1 year. Freedom from target lesion revascularization was 96.2% at 6 months, 81.0% at 1 year, and 60.8% at 2 years. Forty patients experienced major adverse events, exclusively target lesion revascularization. Before treatment, 81.1% of patients had Rutherford scores >= 3; at 2 years, 60.9% of patients had Rutherford scores